Pharmazz, a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited, one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment).